Benzinga | May 13, 2021 07:41AM EDT

UroGen Pharma Q1 EPS $(1.17) Beats $(1.29) Estimate, Sales $7.50M Miss $9.05M Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.29) by 9.3 percent. This is a 34.64 percent increase over losses of $(1.79) per share from the same period last year. The company reported quarterly sales of $7.50 million which missed the analyst consensus estimate of $9.05 million by 17.13 percent.